GalaxoSmithKline (GSK) has announced an expansion of its Mississauga manufacturing facility that will see more than $33.6 million invested in expanding the pharmaceutical company's production. The plant already employs more than 300 staff, and the expansion, according to a company spokesperson, will see 70 new jobs created at the facility.
The global pharmaceutical giant has had a presence in Ontario for more than 100 years, and manufactures pharamaceutical "foams,
ointments, lotions, liquids and other niche products" here, according a statement by GSK VP of Global Manufacturing and Supply Sue West. The expansion will introduce production of carvedilol tablets, zanamivir dry powder inhalation and new dermatological products.
In addition to more than $30 million in investment from GSK, the project is receiving a grant of $3.6 million from the provincial government. "GlaxoSmithKline's efforts to create a global centre of innovation here in Mississauga will create and protect hundreds of jobs," said Innovation Minister Glen Murray in a statement.
Writer: Edward Keenan
Source: Ralph Benmergui, Office of Minister of Innovation Glen Murray